Chatterton J E, Phillips M L, Curtiss L K, Milne R, Fruchart J C, Schumaker V N
Department of Chemistry and Biochemistry, University of California, Los Angeles 90095, USA.
J Lipid Res. 1995 Sep;36(9):2027-37.
In the present study, the relative positions of 11 anti-apolipoprotein B monoclonal antibodies have been mapped onto the surface of human low density lipoproteins by electron microscopy. As the epitopes recognized by these antibodies have been previously located on the primary sequence of apoB, these data provide a map of the configuration of the protein on the surface of the LDL. The first 89% of apoB-100 may be modeled as a thick ribbon that wraps once around the LDL, completing the encirclement by about amino acid residue 4050. The thickness of the ribbon is sufficient to penetrate the monolayer, so that it makes contact with the core. There is a kink in the ribbon beginning almost halfway along its length at approximately apoB-48. The C-terminal 11% of apoB constitutes the "bow," an elongated structure of about 480 residues, beginning at 4050 and stretching back into one hemisphere and then crossing the ribbon into the other hemisphere between residues 3000 to 3500, thus bringing sequences in the C-terminal portion of apoB-100 near to the suggested binding site for the LDL receptor. The C-terminal sequences may act as a negative regulator of LDL receptor binding, in agreement with Parhofer et al, 1992. J. Clin. Invest. 89: 1931-1937, who reported the enhanced clearance from plasma of apoB-89-containing lipoproteins. It is proposed that in VLDL the bow could function to inhibit binding to the receptor; during lipolysis to form LDL, it is suggested that these C-terminal inhibitory sequences forming the bow would move sufficiently to allow interaction with the LDL-receptor.
在本研究中,通过电子显微镜已将11种抗载脂蛋白B单克隆抗体的相对位置定位到人低密度脂蛋白表面。由于这些抗体识别的表位先前已定位在载脂蛋白B的一级序列上,这些数据提供了低密度脂蛋白表面蛋白质构象图。载脂蛋白B-100的前89%可模拟为一条厚带,它围绕低密度脂蛋白缠绕一圈,在大约氨基酸残基4050处完成环绕。带的厚度足以穿透单层,从而与核心接触。在带中大约沿着其长度的一半处,即大约在载脂蛋白B-48处有一个扭结。载脂蛋白B的C末端11%构成“弓形结构”,这是一个约480个残基的细长结构,从4050处开始,向后延伸到一个半球,然后在残基3000至3500之间穿过带进入另一个半球,从而使载脂蛋白B-100 C末端部分的序列靠近低密度脂蛋白受体的假定结合位点。与Parhofer等人(1992年,《临床研究杂志》89:1931 - 1937)的研究一致,C末端序列可能作为低密度脂蛋白受体结合的负调节剂,他们报道了含载脂蛋白B-89的脂蛋白从血浆中清除增强。有人提出,在极低密度脂蛋白中,弓形结构可能起到抑制与受体结合的作用;在脂解形成低密度脂蛋白的过程中,有人认为形成弓形结构的这些C末端抑制序列会充分移动,以允许与低密度脂蛋白受体相互作用。